Minerva Neurosciences | NERV - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Adma Biologics USD 73.54M 4M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cipla INR 70.14B 7.16B 2026-03
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.57M 2.29M 2025-12
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novavax USD 342.46M 117.49M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.43T 180.65B 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12